TY - JOUR
T1 - Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine
AU - Amir, Ofra
AU - Goldberg, Yair
AU - Mandel, Micha
AU - Bar-On, Yinon M.
AU - Bodenheimer, Omri
AU - Ash, Nachman
AU - Alroy-Preis, Sharon
AU - Huppert, Amit
AU - Milo, Ron
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Israel began administering a BNT162b2 booster dose to restore protection following the waning of the 2-dose vaccine. Biological studies have shown that a “fresh” booster dose leads to increased antibody levels compared to a fresh 2-dose vaccine, which may suggest increased effectiveness. To compare the real-world effectiveness of a fresh (up to 60 days) booster dose with that of a fresh 2-dose vaccine, we took advantage of a quasi-experimental study that compares populations that were eligible to receive the vaccine at different times due to age-dependent policies. Specifically, we compared the confirmed infection rates in adolescents aged 12–14 (215,653 individuals) who received the 2-dose vaccine and in adolescents aged 16–18 (103,454 individuals) who received the booster dose. Our analysis shows that the confirmed infection rate was lower by a factor of 3.7 (95% CI: 2.7 to 5.2) in the booster group.
AB - Israel began administering a BNT162b2 booster dose to restore protection following the waning of the 2-dose vaccine. Biological studies have shown that a “fresh” booster dose leads to increased antibody levels compared to a fresh 2-dose vaccine, which may suggest increased effectiveness. To compare the real-world effectiveness of a fresh (up to 60 days) booster dose with that of a fresh 2-dose vaccine, we took advantage of a quasi-experimental study that compares populations that were eligible to receive the vaccine at different times due to age-dependent policies. Specifically, we compared the confirmed infection rates in adolescents aged 12–14 (215,653 individuals) who received the 2-dose vaccine and in adolescents aged 16–18 (103,454 individuals) who received the booster dose. Our analysis shows that the confirmed infection rate was lower by a factor of 3.7 (95% CI: 2.7 to 5.2) in the booster group.
UR - http://www.scopus.com/inward/record.url?scp=85128304908&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-29578-w
DO - 10.1038/s41467-022-29578-w
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35418201
AN - SCOPUS:85128304908
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1971
ER -